Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Interaction: Mechanistic Insights and Research Implications

Study Background and Research Question

The renin-angiotensin system (RAS) is foundational to cardiovascular and renal physiology, regulating blood pressure and fluid balance via a cascade of peptide hormones. Angiotensin II (1–8), a central effector of this pathway, is known for its potent vasoconstrictive and dipsogenic actions. Fragments of angiotensin II, such as Angiotensin 1/2 (5-7) (the H2N-Ile-His-Pro-OH peptide), have been utilized to probe RAS signaling in diverse biological contexts. Amidst the COVID-19 pandemic, attention has turned to the intersection of RAS peptides and viral pathogenesis, particularly given that SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as a primary entry receptor. The reference study by Oliveira et al. (2025) seeks to clarify whether naturally occurring angiotensin peptides influence the binding affinity of the SARS-CoV-2 spike protein to its cellular receptors, including the alternative receptor AXL, and to delineate the mechanistic underpinnings of this interaction (Oliveira et al., 2025).

Key Innovation from the Reference Study

The central innovation of Oliveira et al. is the discovery that specific natural angiotensin peptide fragments can enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor—a process distinct from interaction with the canonical ACE2 receptor. Notably, shorter C- and N-terminal fragments, including those resembling Angiotensin 1/2 (5-7), exerted even greater enhancement than full-length angiotensin II. This finding suggests a previously unrecognized role for RAS-derived peptides in modulating viral receptor engagement, with implications for both cardiovascular and infectious disease research.

Methods and Experimental Design Insights

The study employed a combination of antibody-based binding assays to quantify the interaction between the SARS-CoV-2 spike protein and its cellular receptors (AXL, ACE2, and NRP1) in the presence of various angiotensin peptides. The experimental design included:

• Use of recombinant spike protein and cellular receptor proteins to establish controlled binding conditions.
• Systematic C- and N-terminal truncation of angiotensin II (1–8) to generate fragments such as angiotensin (1–7), angiotensin (1–6), angiotensin III (2–8), angiotensin IV (3–8), angiotensin (2–7), and angiotensin (5–7).
• Assessment of spike–receptor binding in the presence of each peptide fragment, with quantitative readouts comparing fold-changes against controls.
• Evaluation of the effects of amino acid substitutions and post-translational modifications (e.g., tyrosine phosphorylation or substitution) on binding enhancement.

This approach enabled the dissection of structure–activity relationships, revealing which peptide moieties are critical for the observed potentiation of spike–AXL interaction.

Core Findings and Why They Matter

The main findings of the reference study are as follows:

• Angiotensin II (1–8) increased spike–AXL binding two-fold, while not affecting spike–ACE2 or spike–NRP1 binding under the same conditions (Oliveira et al., 2025).
• Shorter peptide fragments, especially those generated by N-terminal cleavage (e.g., angiotensin IV (3–8), angiotensin (5–7)), produced an even greater enhancement (>2.7-fold for angiotensin IV) of spike–AXL binding.
• C-terminal truncations (e.g., angiotensin (1–7), angiotensin (1–6)) preserved or increased potentiating activity, while some N-terminal deletions had an additive effect.
• The presence of tyrosine at position 4 was particularly important: both substitution (with valine) and phosphorylation of this residue further increased spike–AXL binding.
• Among the tested fragments, the H2N-Ile-His-Pro-OH peptide (Angiotensin 1/2 (5-7)) demonstrated a distinct capacity to enhance spike–AXL interaction, underscoring the biological relevance of this minimal motif within the RAS peptide family.

These results suggest that circulating and locally generated angiotensin fragments can modulate viral–host interactions in ways that extend beyond classical vasoconstrictor peptide hormone functions. Such activity may have pathophysiological significance in COVID-19, where altered RAS activity and peptide profiles have been reported in severe cases.

Comparison with Existing Internal Articles

Internal resources offer practical and methodological guidance for leveraging Angiotensin 1/2 (5-7) in laboratory workflows. For example, one scenario-driven article discusses how the H2N-Ile-His-Pro-OH peptide can be integrated into cell viability, proliferation, and cytotoxicity assays to improve sensitivity and reproducibility in renin-angiotensin system research. This aligns with the reference study's finding that short angiotensin fragments possess distinct biological activities, including novel effects on viral receptor binding.

Another resource, "Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding", directly contextualizes the mechanistic bridge between RAS peptide research and viral pathogenesis, further affirming the translational relevance of Oliveira et al.'s findings. By integrating these perspectives, researchers are equipped with both mechanistic insight and practical protocols for experimental design.

Limitations and Transferability

While Oliveira et al. provide compelling in vitro evidence for angiotensin peptide-mediated potentiation of spike–AXL binding, several limitations should be noted:

• The study is restricted to biochemical and cell-free assays; in vivo relevance, peptide pharmacokinetics, and physiological concentrations remain to be fully elucidated.
• The exact downstream consequences of enhanced spike–AXL interaction—such as increased infectivity or altered tissue tropism—were not directly assessed.
• The observed effects may depend on local peptide concentrations and tissue-specific expression of RAS components and viral receptors.

Therefore, while the mechanistic link is robust in experimental systems, translation to clinical or organismal contexts must be approached cautiously.

Why this cross-domain matters, maturity, and limitations

This study bridges cardiovascular peptide hormone research with viral infection biology, offering new mechanistic hypotheses for COVID-19 severity and susceptibility in patients with altered RAS profiles. The evidence is at a preclinical, mechanistic stage, and further work is needed to validate these findings in physiological and pathological models.

Protocol Parameters

• Peptide concentration for binding assays: 1–10 µM, as supported by the reference study for detecting enhanced spike–AXL interaction.
• Solubility considerations: Prepare Angiotensin 1/2 (5-7) at concentrations up to 50 mg/mL in water or ethanol, or 36.5 mg/mL in DMSO, to ensure complete dissolution (product information).
• Short-term storage: Store peptide solutions at -20°C and use promptly to minimize degradation; solid peptide is stable for longer-term storage.
• Experimental controls: Include vehicle controls and, where possible, full-length angiotensin II (1–8) for comparative analysis of fragment activity.

Research Support Resources

For researchers seeking to reproduce or extend these findings, Angiotensin 1/2 (5-7) (SKU A1049) is available at high purity for use in binding, signaling, and viability assays. The H2N-Ile-His-Pro-OH peptide is widely adopted in renin-angiotensin system and hypertension research, and its solubility profile supports diverse experimental workflows. For further discussion of practical design and troubleshooting, scenario-driven guidance is available in internal methodological articles.